Hematologic Malignancy
Childhood Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
CI-CAN-00004882Explore in graph →
PediatricHematologic1 active trials
- NCIt
- C5637
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00004882Explore in graph →
Clinical trials
29 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (4)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00354107 | Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Mar 14, 2018 | clinicaltrials |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia | terminated | Phase 1 | 129 | National Cancer Institute (NCI)NIH | 2 | Nov 5, 2014 |
| clinicaltrials |
| NCT00933985 | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia | terminated | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 2 | May 1, 2014 | clinicaltrials |
| NCT00101205 | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | terminated | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Mar 14, 2018source: clinicaltrials